Recent Updates
Recently added Catalysts

Generic H/A taken first

Phase 2

Opioid-Related Disorders | Small Molecules | Psychiatry |Acura Pharmaceuticals Inc|Trials Updated: Nov 1, 2018

Generic H/A taken first development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jan 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Generic H/A taken first clinical trials

Generic H/A taken first · 1 trial · 1 indication

Phase 2 1
NCT01759446Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid UsersOpioid-Related Disorders
COMPLETED44 Analytics
PHASE2COMPLETED
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related DisordersUnlock trial analytics

Study Endpoints

Primary Endpoints

Emax - Maximum Drug Liking
8 hours

"Do you dislike or like the drug effect you are feeling now?" The question is scored using a 100-point bipolar visual analog scale (VAS) anchored in the center with "neither like nor dislike" (score of 50), on the left with "Strong Disliking" (score of 0) and on the right with "Strong Liking" (score of 100). Maximum Score. Assessment were made at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dosing.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Placebo taken firstPLACEBO_COMPARATORPlacebo powder snorted with all other arms taken crossover therafter
Generic H/A taken firstACTIVE_COMPARATORGeneric hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
Vycavert taken firstACTIVE_COMPARATORVycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
Generic H/A plus i taken firstACTIVE_COMPARATORGeneric hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
Generic H/A plus p taken firstACTIVE_COMPARATORGeneric hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter

Interventions

NameTypeDescription
Placebo taken firstDRUGSnorted in both nostrils within 5 minutes; 48 hours washout between doses
Generic H/A taken firstDRUGSnorted in both nostrils within 5 minutes; 48 hours washout between doses
Vycavert taken firstDRUGSnorted in both nostrils within 5 minutes; 48 hours washout between doses
Generic H/A plus i taken firstDRUGSnorted in both nostrils within 5 minutes; 48 hours washout between doses
Generic H/A plus p taken firstDRUGSnorted in both nostrils within 5 minutes; 48 hours washout between doses
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG...

Countries:United States
Unlock Eligibility Criteria